SCHEMBL2199352

SCHEMBL2199352

Cc1ccc(NC(=O)Nc2ccccc2)cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 9/20 0.63
MAPK12 P53778 9/20 0.63
MAPK11 Q15759 9/20 0.63
MAPK14 Q16539 9/20 0.63
SMN1; SMN2 Q16637 4/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
HTT P42858 1/20 0.53
AVPR2 P30518 1/20 0.52
OXTR P30559 1/20 0.52
AVPR1A P37288 1/20 0.52
MAPT P10636 1/20 0.51
IDH1 O75874 2/20 0.46
GAA P10253 1/20 0.46
KDM4E B2RXH2 1/20 0.45
KLK7 P49862 1/20 0.45
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2199284 0.90 MAPT (0.59) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2
SCHEMBL2199250 0.90 NPC1 (0.59) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2
SCHEMBL2200476 0.89 MAPK13 (0.57) MAPK13MAPK12MAPK11MAPK14NPC1
SCHEMBL2197054 0.89 MAPK13 (0.55) MAPK13MAPK12MAPK11MAPK14IDH1
SCHEMBL2203090 0.88 MAPK13 (0.59) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2
SCHEMBL2203132 0.88 MAPK13 (0.54) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2
SCHEMBL2199258 0.88 MAPK14 (0.55) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2
SCHEMBL2197594 0.87 MAPK13 (0.61) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2
SCHEMBL2196210 0.87 MAPK13 (0.57) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2
SCHEMBL2581412 0.87 MAPK13 (0.58) MAPK13MAPK12MAPK11MAPK14SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP claimed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US claimed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP claimed
JP-2006528597-A 2006-12-21 JP claimed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US claimed
EP-1658263-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS Leo Pharma A/S (DK) 2006-05-24 EP claimed
WO-2005009940-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA A/S (DK) 2005-02-03 WO claimed
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed
EP-1658263-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS Leo Pharma A/S (DK) 2006-05-24 EP disclosed
WO-2005009940-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA A/S (DK) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 MAPK13 1063/4885MAPK12 955/4885MAPK11 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.